Pharmacovigilance [Pharmacovigilance update]

Details

Ressource 1Request a copyDownload: BIB_61D54069EC5E.P001.pdf (544.09 [Ko])
State: Deleted
Version: author
Serval ID
serval:BIB_61D54069EC5E
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Pharmacovigilance [Pharmacovigilance update]
Journal
Revue medicale suisse
Author(s)
Dao K., Chtioui H., Rothuizen L.E., Diezi L., Prod'hom S., Winterfeld U., Buclin T., Livio F.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Publication state
Published
Issued date
13/01/2016
Volume
12
Number
500
Pages
75-79
Language
french
Notes
Publication types: English Abstract ; Journal Article
Publication Status: ppublish
Abstract
Les actualités de pharmacovigilance 2015 sont passées en revue. Interaction sofosbuvir-amiodarone : risque de bradycardie sévère. Interaction dasabuvir-clopidogrel : surexposition au dasabuvir et risque potentiel d’allongement du QT. Inhibiteurs SGLT2 (cotransporteur sodium-glucose de type 2) : risque d’acidocétose diabétique et de fracture osseuse. Dabigatran : rapport bénéfice-risque amélioré par un monitoring. Ibuprofène : à dosage élevé, risque cardiovasculaire équivalent aux coxibs. Prégabaline, gabapentine : potentiel d’abus et de dépendance. Varénicline : augmentation des effets de l’alcool. Codéine : contre-indiquée chez les moins de douze ans comme antitussif. Valproate : nouvelles mises en garde sur les risques d’une exposition durant la grossesse. Diméthylfumarate : rares cas de leucoencéphalopathie multifocale progressive. Ustékinumab : rares cas d’érythrodermie.
[The main pharmacovigilance updates in 2015are reviewed. Sofosbuvir amiodarone interaction: risk of severe bradycardia. Dasabuvir clopidogrel interaction: increased dasabuvir concentrations and potential risk of QTprolongation. SGLT2 inhibitors: risks of diabetic acidocetosis and bone fracture. Dabigatran: therapeutic drug monitoring may improve benefit-risk ratio. Ibuprofen: at higher dosage, vascular risks are comparable to coxibs. Pregabaline, gabapentine: potential for abuse and addiction. Varenicline: potentiates alcohol's effects. Codeine: contra-indicated as cough medicine under the age of twelve. Valproate: strengthened warnings on the risks of valproate use in pregnancy. Dimethylfumarate: rare observations of progressive multifocal leucoencephalopathy. Ustekinumab: rare observations of erythrodermia.]

Keywords
Drug Monitoring/methods, Drug-Related Side Effects and Adverse Reactions/etiology, Humans, Pharmacovigilance
Pubmed
Create date
26/01/2016 15:41
Last modification date
20/08/2019 15:18
Usage data